EnVVeno Medical : Corporate Presentation

Setting New Standards for Venous Care

October 2021

Investor Presentation

Nasdaq: NVNO enVVeno.com

Legal Disclaimers
2

This presentation and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to our name change, our progress with the VenoValve® and the expected timeline related to the SAAVE U.S. pivotal trial, including the timing of beginning patient enrollment, the VenoValve®'s ability to fill the unmet medical needs of CVI sufferers and our development of a second device for the treatment of venous disease) may differ significantly from those set forth or implied in the forward-looking statements. These forward- looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Nasdaq: NVNO | enVVeno.com

Investment Highlights
3

Lead product candidate, VenoValue® being evaluated for the treatment

of lower limb deep venous Chronic Venous Insufficiency (CVI)

Demonstrated efficacy and safety		Ongoing SAVVE pivotal trial with		Sufficient capital to fund operations
in first-in-human trial		data expected Q4 2022		through pivotal data readout

Nasdaq: NVNO | enVVeno.com

4

Potential to redefine the standard of care in lower limb Chronic Venous Insufficiency (CVI)

Breakthrough Device Designation

Significant opportunity with

~2.4 million potential patients in the U.S.

enVVeno.com

5

View Video

Nasdaq: NVNO | enVVeno.com